| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.005 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.006 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.006 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.3 | 0.006 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.077 | 0.006 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.006 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.007 |